Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael E Abram

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Journal of Virology|September 6, 2005
Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domainMichael E Abram, Michael A Parniak
Retrovirology|February 4, 2010
The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage siteMichael E Abram, Stefan G Sarafianos, Michael A Parniak
The International Journal of Biochemistry & Cell Biology|June 9, 2004
Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formationNicolas Sluis-Cremer, Dominique Arion, Michael E Abram, et al.
BMC Genomics|February 12, 2022
Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequencesÁine O'Toole, Oliver G Pybus, Michael E Abram, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2014
A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitorsMichael E Abram, Manuel Tsiang, Kirsten L White, et al.
Journal of Medical Virology|August 8, 2019
Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individualsNicolas A Margot, Renee R Ram, Kirsten L White, et al.
Journal of Virology|July 28, 2010
Nature, position, and frequency of mutations made in a single cycle of HIV-1 replicationMichael E Abram, Andrea L Ferris, Wei Shao, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2015
Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimenKristen Andreatta, Rima Kulkarni, Michael E Abram, et al.
The Journal of Biological Chemistry|October 31, 2001
Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazonesDominique Arion, Nicolas Sluis-Cremer, Kyung-Lyum Min, et al.
The Journal of Infectious Diseases|April 29, 2017
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir AlafenamideNicolas A Margot, Pamela Wong, Rima Kulkarni, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Journal of Virology|September 6, 2005
Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domainMichael E Abram, Michael A Parniak
Retrovirology|February 4, 2010
The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage siteMichael E Abram, Stefan G Sarafianos, Michael A Parniak
The International Journal of Biochemistry & Cell Biology|June 9, 2004
Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formationNicolas Sluis-Cremer, Dominique Arion, Michael E Abram, et al.
BMC Genomics|February 12, 2022
Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequencesÁine O'Toole, Oliver G Pybus, Michael E Abram, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2014
A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitorsMichael E Abram, Manuel Tsiang, Kirsten L White, et al.
Journal of Medical Virology|August 8, 2019
Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individualsNicolas A Margot, Renee R Ram, Kirsten L White, et al.
Journal of Virology|July 28, 2010
Nature, position, and frequency of mutations made in a single cycle of HIV-1 replicationMichael E Abram, Andrea L Ferris, Wei Shao, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2015
Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimenKristen Andreatta, Rima Kulkarni, Michael E Abram, et al.
The Journal of Biological Chemistry|October 31, 2001
Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazonesDominique Arion, Nicolas Sluis-Cremer, Kyung-Lyum Min, et al.
The Journal of Infectious Diseases|April 29, 2017
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir AlafenamideNicolas A Margot, Pamela Wong, Rima Kulkarni, et al.
Pageof 4